Nuvation Bio Inc.
NUVB
Rank in Stocks
#6935
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise... Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Share Price
$4.35
Last synced: 2026-11-09
Market Cap
$1.53B
Change (1 day)
4.57%
Change (1 year)
-12.65%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Nuvation Bio Inc. (NUVB)
Category
Healthcare
Operating Margin for Nuvation Bio Inc. (NUVB)
Operating Margin as of November 2026 TTM: -81.00%
According to Nuvation Bio Inc.'s latest financial reports, its current operating margin (TTM) is -81.00%. At the end of 2025 the company had an operating margin of -338.72%.
Operating Margin history for Nuvation Bio Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -81.00% | -76.09% |
| 2025 | -338.72% | -95.50% |
| 2024 | -7,527.33% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.48% |
US
|
|
| -149.01% | -98.16% |
US
|
|
| 25.57% | -100.32% |
AU
|
|
| 31.23% | -100.39% |
BE
|
|
| 29.35% | -100.36% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Nuvation Bio Inc.'s operating margin
What is Nuvation Bio Inc.'s operating margin?
Nuvation Bio Inc.'s operating margin is -81.00%, as of Nov 2026.
What was Nuvation Bio Inc.'s operating margin in 2025?
In 2025, Nuvation Bio Inc.'s operating margin was -338.72%, compared with -7,527.33% in 2024.
How has Nuvation Bio Inc.'s operating margin changed since 2020?
From 2020 to 2025, Nuvation Bio Inc.'s operating margin was highest in 2023 (0.00%) and lowest in 2024 (-7,527.33%).
How does Nuvation Bio Inc.'s operating margin compare with similar companies?
Nuvation Bio Inc.'s operating margin (-81.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.